Level D· Scientific groundwork from lab and animal studiesNarrative ReviewEurope PMC

Biological activities of astaxanthin in the treatment of neurodegenerative diseases

Lotfi A., Abroodi Z., Khazaei M.

Narrative Review on Neuroinflammation, Chronic Inflammation, published in Neurodegener Dis Manag (2024) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Neurodegener Dis Manag (2024)
Reported sample size
—
Source database
Europe PMC
PMID
39648516
PMCID
PMC11703140
DOI
10.1080/17582024.2024.2433932
Citations
3

Abstract (original English)

Introduction Neurodegenerative diseases (NDs) develop with the gradual advancement of neuronal damage and dysfunction in the central nervous system (CNS). These disorders are mostly the outcomes of the improper sedimentation and accumulation of proteins, such as amyloid-β (Aβ), α-synuclein, and prions. Astaxanthin (AST) exists in different types of living organisms and displays antioxidant and anti-inflammatory functions. This review has concentrated on the therapeutic characteristics of AST on NDs. Methods Data was collected by searching Scopus, PubMed, and Google Scholar databases. Articles selected for this review reported results on the neuroprotective properties of AST on NDs of studies conducted during the years 2000 to 2024. Results AST decreases soluble Aβ levels by stimulating the Aβ degradation enzyme. It also reduces inflammation in the substantia nigra (SN) by decreasing IBA1 expression, thereby lessening microglia activity. This carotenoid reduces demyelination by increasing the survival of oligodendrocytes cells and increasing the number of their progenitor cells. AST has antioxidant, anti-inflammatory, and anti-apoptotic properties and can play a role in the treatment of many NDs. Conclusion There is no definitive treatment for some NDs. The use of AST and natural compounds can be an optimal method for preventing and treating NDs with few side effects.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsHumansNeurodegenerative DiseasesXanthophyllsNeuroprotective AgentsAnti-Inflammatory AgentsAntioxidants

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research